Daytime vs. Delayed Eating Among Obese Individuals

November 10, 2025 updated by: Kelly Allison, University of Pennsylvania

Randomized Controlled Trial Examining the Effects of Meal Timing Among Obese Individuals

The randomized, cross-over design study is designed to determine how timing of eating affects weight, adiposity, energy metabolism, and gene expression. Obese participants will be provided isocaloric meals and snacks to be consumed in one of two prescribed eating conditions -- daytime eating and delayed eating.

Study Overview

Detailed Description

The study consists of the following phases - screening, assessment visit 1, eating condition 1, assessment visit 2, a wash-out period, assessment visit 3, eating condition 2 and assessment visit 4, as discussed in detail below. The assessment visits will all consist of the same procedures and will take place at the Center for Human Phenomic Science (CHPS) of the Hospital of the University of Pennsylvania before and after each of the eating conditions (four times total). The four 28-hour inpatient assessments will consist of blood draws, adipose (fat) tissue sampling, a dual energy X-ray absorptiometry (DEXA) scan, and a resting metabolic rate test.

During the screening period in order to determine eligibility, participants must complete a 2-part screening visit; This includes:

  1. A complete physical examination
  2. Tests of blood to screen for any conditions such as diabetes or any serious, uncontrolled medical condition that may interfere with participation in the study.
  3. An Electrocardiogram (EKG) test
  4. Urine Pregnancy Test
  5. Urine Drug Screening
  6. the completion of several self-report questionnaires and structured interviews

During the screening period, participants will also be asked to keep a 10-day food log where they will record all food and beverages consumed and their sleep and exercise schedule. Participants will be asked to wear an Actigraph wrist watch at this time.

Following successful completion of the screening period, participants will complete the first of 4 assessment visits. All assessment visits will follow the same protocol.

Assessment Visit Day 1 Procedures:

The visit will include 28 hours (overnight) spent at the CHPS, where meals and snacks will be provided. At each of the assessment visits participants will be given a urine drug screening and, if appropriate, a pregnancy test. The lights will be dim in the hospital room to control for light.

Participants will arrive at 7:00 am. Starting at 8:00 am, blood will be drawn every four hours. From this blood gene expression and hormones related to metabolism, eating, and sleep will be measured.

Following the first blood draw, resting metabolic rate is measured for 45 minutes. Lunch is then provided, followed by a measurement of body composition using a DEXA scan. Next, the adipose tissue sampling procedure will begin. Lastly, the participants will complete a series of cognitive tests administered on a laptop.

Participants will be provided meals and snacks during their visit and are free to watch television or participate in other sedentary pastimes while they are there.

Assessment Visit Day 2 Procedures:

After an overnight fast, participants will undergo the Frequently Sampled Intravenous Glucose Tolerance Test (FSIGT) on the morning of day 2.

Following the FSIGT test, participants will be served a meal and during the first assessment visit, participants will be randomly assigned to start with one of two eating conditions for the next 8 weeks: 1) Daytime or 2) Delayed. Following randomization, participants will be discharged from CHPS and begin eating condition 1.

If participants are assigned to the daytime eating condition first, they will be asked to consume all of their meals and snacks each day between 8:00 am and 7:00 pm. If they are assigned to the delayed eating condition first, they will be asked to consume all of their meals and snacks between 12 noon and 11:00 pm each day. Participants will eat on this schedule for 8 weeks. During the two, 8-week eating periods, all of the meals and snacks will be provided by the research kitchen. During the eating conditions, participants will be asked to complete daily self-report queries concerning their adherence to the food, sleep, and physical activity requirements of the study.

Following eating condition 1, participants will return for assessment visit 2. This assessment visit follows the same procedures as all other assessment visits. Following assessment visit 2, participants will begin their 2 week washout period where they are instructed to eat as they normally would whenever they like. Following the two-week washout period, participants will return for assessment visit 3, after which they will begin eating condition 2. Following 8 weeks of eating condition 2 participants will return for their final visit, assessment visit 4. After this final assessment, participation in the study will be complete.

Study Type

Interventional

Enrollment (Actual)

38

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

    • Pennsylvania
      • Philadelphia, Pennsylvania, United States, 19104
        • Center for Weight and Eating Disorders, Perelman School of Medicine, University of Pennsylvania

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

21 years to 50 years (Adult)

Accepts Healthy Volunteers

Yes

Description

Inclusion Criteria:

  • age 21-50
  • BMI of 30-50 kg/m2
  • stable weight (±10 lb) over the previous 6 months
  • women must be pre-menopausal with regular menstrual cycles

Exclusion Criteria:

  • unstable, serious medical conditions
  • use of medicine linked to weight gain/loss
  • cardiac conditions
  • cancer
  • diabetes
  • autoimmune disease
  • use of illicit drugs, melatonin, diuretics or hypnotics
  • involved in a current weight loss program
  • presence of an untreated sleep disorder (determined by surveys and actigraphy)
  • those who work shift work
  • those with extreme chronotypes
  • habitual waking outside of 0600h-0930h
  • habitual bedtime <2200h or >2400h
  • sleep duration of <6.5 or >8.5 h/night.
  • psychiatric exclusions will be: depression (Patient Health Questionnaire-9 score ≥9), lifetime bipolar disorder, psychosis, or eating disorder; or any other severe psychiatric disorder judged to interfere with study adherence as assessed by the MINI International Neuropsychiatric Interview.
  • structured exercise >3 d/wk, for >30 min measured by exercise logs and actigraphy; normal activity levels are required during the study (±30 min/wk of baseline level).

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Other
  • Allocation: Randomized
  • Interventional Model: Crossover Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Daytime Eating Condition
Participants will be asked to eat all of their meals and snacks, as provided by the study, between 0800 and 1900.
Participants will be randomly assigned to eat per the prescribed eating condition for 8 weeks during eating condition 1. They will complete the alternate eating condition for 8 weeks during eating condition 2.
Experimental: Delayed Eating Condition
Participants will be asked to eat all of their meals and snacks, as provided by the study, between 1200 and 2300.
Participants will be randomly assigned to eat per the prescribed eating condition for 8 weeks during eating condition 1. They will complete the alternate eating condition for 8 weeks during eating condition 2.
Other: Withdrawn before randomization
Two participants completed the screening process and started the first inpatient assessment visit but were withdrawn prior to completion of the assessment visit and were not randomized to start the intervention. They were not included in data analysis.
These participants were withdrawn and did not receive an intervention.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Body Mass (Weight)
Time Frame: pre-post changes between the daytime and delayed eating conditions (each 8 weeks long)
changes in body mass, as measured by a calibrated digital scale, will be explored.
pre-post changes between the daytime and delayed eating conditions (each 8 weeks long)
Adiposity - Total Body Fat
Time Frame: pre-post changes between the daytime and delayed eating conditions (8 weeks).
changes in measures of total body fat, as measured by a DEXA scan, will be explored.
pre-post changes between the daytime and delayed eating conditions (8 weeks).
Energy Homeostasis Outcomes - REE
Time Frame: pre-post changes between the daytime and delayed eating conditions (8 weeks).
Changes in resting energy expenditure values will be explored.
pre-post changes between the daytime and delayed eating conditions (8 weeks).
Energy Homeostasis - Respiratory Quotient
Time Frame: pre-post changes between the daytime and delayed eating conditions (8 weeks).
Respiratory quotient (RQ) was measured with a Parvo-Medics metabolic cart. It is calculated from the ratio of carbon dioxide produced by the body to oxygen consumed by the body, when the body is in a steady state.
pre-post changes between the daytime and delayed eating conditions (8 weeks).

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
circadian ghrelin rhythms
Time Frame: pre-post changes between the daytime and delayed eating conditions (8 weeks).
differences in circadian ghrelin rhythms will be explored.
pre-post changes between the daytime and delayed eating conditions (8 weeks).
circadian leptin rhythms
Time Frame: pre-post changes between the daytime and delayed eating conditions (8 weeks).
differences in circadian leptin rhythms will be explored.
pre-post changes between the daytime and delayed eating conditions (8 weeks).
gene expression profiles
Time Frame: pre-post changes between the daytime and delayed eating conditions (8 weeks).
differences in the phase and cycling of gene expression profiles will be explored.
pre-post changes between the daytime and delayed eating conditions (8 weeks).
insulin sensitivity
Time Frame: pre-post changes between the daytime and delayed eating conditions (8 weeks).
changes in insulin sensitivity will be explored.
pre-post changes between the daytime and delayed eating conditions (8 weeks).
free fatty acid dynamics
Time Frame: pre-post changes between the daytime and delayed eating conditions (8 weeks)
changes in free fatty acid dynamics will be explored.
pre-post changes between the daytime and delayed eating conditions (8 weeks)
adipose tissue gene expression
Time Frame: pre-post changes between the daytime and delayed eating conditions (8 weeks)
changes in adipose tissue gene expression will be explored.
pre-post changes between the daytime and delayed eating conditions (8 weeks)

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Principal Investigator: Kelly Allison, PhD, University of Pennsylvania

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

February 7, 2018

Primary Completion (Actual)

March 2, 2023

Study Completion (Actual)

March 2, 2023

Study Registration Dates

First Submitted

November 21, 2017

First Submitted That Met QC Criteria

November 21, 2017

First Posted (Actual)

November 27, 2017

Study Record Updates

Last Update Posted (Estimated)

November 21, 2025

Last Update Submitted That Met QC Criteria

November 10, 2025

Last Verified

November 1, 2025

More Information

Terms related to this study

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Obesity

Clinical Trials on Eating Condition

Subscribe